Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures
Identifieur interne : 005407 ( Main/Merge ); précédent : 005406; suivant : 005408Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures
Auteurs : Anthony S. Fauci [États-Unis]Source :
- The Journal of Infectious Diseases [ 0022-1899 ] ; 2006.
Descripteurs français
- KwdFr :
- Académies et instituts (tendances), Adulte, Animaux, Antienzymes (administration et posologie), Antienzymes (usage thérapeutique), Antiviraux (usage thérapeutique), Association de médicaments, Essais cliniques comme sujet, Flambées de maladies (), Grippe humaine (), Grippe humaine (traitement médicamenteux), Humains, Infections à Orthomyxoviridae (), Infections à Orthomyxoviridae (traitement médicamenteux), Nourrisson, Oséltamivir (usage thérapeutique), Planification en santé, Saisons, Santé mondiale, Sialidase (antagonistes et inhibiteurs), Sialidase (usage thérapeutique), Vaccination (tendances), Vaccins antigrippaux (administration et posologie), Virus de la grippe A (immunologie), États-Unis d'Amérique (épidémiologie).
- MESH :
- administration et posologie : Antienzymes, Vaccins antigrippaux.
- antagonistes et inhibiteurs : Sialidase.
- immunologie : Virus de la grippe A.
- tendances : Académies et instituts, Vaccination.
- traitement médicamenteux : Grippe humaine, Infections à Orthomyxoviridae.
- usage thérapeutique : Antienzymes, Antiviraux, Oséltamivir, Sialidase.
- épidémiologie : États-Unis d'Amérique.
- Adulte, Animaux, Association de médicaments, Essais cliniques comme sujet, Flambées de maladies, Grippe humaine, Humains, Infections à Orthomyxoviridae, Nourrisson, Planification en santé, Saisons, Santé mondiale.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Academies and Institutes (trends), Adult, Animals, Antiviral Agents (therapeutic use), Clinical Trials as Topic, Disease Outbreaks (prevention & control), Drug Therapy, Combination, Enzyme Inhibitors (administration & dosage), Enzyme Inhibitors (therapeutic use), Global Health, Health Planning, Humans, Infant, Influenza A virus (immunology), Influenza Vaccines (administration & dosage), Influenza, Human (drug therapy), Influenza, Human (prevention & control), Neuraminidase (antagonists & inhibitors), Neuraminidase (therapeutic use), Orthomyxoviridae Infections (drug therapy), Orthomyxoviridae Infections (prevention & control), Oseltamivir (therapeutic use), Seasons, United States (epidemiology), Vaccination (trends).
- MESH :
- chemical , administration & dosage : Enzyme Inhibitors, Influenza Vaccines.
- chemical , antagonists & inhibitors : Neuraminidase.
- chemical , therapeutic use : Antiviral Agents, Enzyme Inhibitors, Neuraminidase, Oseltamivir.
- geographic , epidemiology : United States.
- drug therapy : Influenza, Human, Orthomyxoviridae Infections.
- immunology : Influenza A virus.
- prevention & control : Disease Outbreaks, Influenza, Human, Orthomyxoviridae Infections.
- trends : Academies and Institutes, Vaccination.
- Adult, Animals, Clinical Trials as Topic, Drug Therapy, Combination, Global Health, Health Planning, Humans, Infant, Seasons.
Abstract
Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has been working to enact measures to deal more effectively with a potential influenza pandemic and also to assist in the management of seasonal influenza. The majority of the NIAID’s efforts have been dedicated to basic research aimed ultimately at developing and testing, in clinical trials, countermeasures in the form of antiviral drugs and vaccines. Some of the NIAID’s current and planned antiviral projects include the (1) assessment of oseltamivir therapy in infants, (2) conduct of clinical trials of higher doses of osteltamivir for avian influenza, (3) appraisal of combination therapies, and (4) evaluation of the next generation of neuraminidase inhibitors. In addition, the NIAID is screening potential new antiviral drugs and evaluating novel drug targets. Similarly, significant funding has been committed to vaccine preparedness, and numerous novel candidate influenza vaccines are in various stages of development. Importantly, there is an integral relationship between preparation for seasonal influenza and preparation for pandemic influenza. Until these approaches are firmly linked, the community will not have optimized its preparedness for a pandemic.
Url:
DOI: 10.1086/507550
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001691
- to stream Istex, to step Curation: 001691
- to stream Istex, to step Checkpoint: 001707
- to stream PubMed, to step Corpus: 001C24
- to stream PubMed, to step Curation: 001C24
- to stream PubMed, to step Checkpoint: 001A62
- to stream Ncbi, to step Merge: 000436
- to stream Ncbi, to step Curation: 000436
- to stream Ncbi, to step Checkpoint: 000436
Links to Exploration step
ISTEX:6FA22D241D5561D559825239E2E3CFCCC62D26F5Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures</title><author wicri:is="90%"><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S." last="Fauci">Anthony S. Fauci</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FA22D241D5561D559825239E2E3CFCCC62D26F5</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1086/507550</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-3K1JXSPC-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001691</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001691</idno><idno type="wicri:Area/Istex/Curation">001691</idno><idno type="wicri:Area/Istex/Checkpoint">001707</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001707</idno><idno type="wicri:doubleKey">0022-1899:2006:Fauci A:seasonal:and:pandemic</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:17163392</idno><idno type="wicri:Area/PubMed/Corpus">001C24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C24</idno><idno type="wicri:Area/PubMed/Curation">001C24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C24</idno><idno type="wicri:Area/PubMed/Checkpoint">001A62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A62</idno><idno type="wicri:Area/Ncbi/Merge">000436</idno><idno type="wicri:Area/Ncbi/Curation">000436</idno><idno type="wicri:Area/Ncbi/Checkpoint">000436</idno><idno type="wicri:doubleKey">0022-1899:2006:Fauci A:seasonal:and:pandemic</idno><idno type="wicri:Area/Main/Merge">005407</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures</title><author wicri:is="90%"><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S." last="Fauci">Anthony S. Fauci</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>University of Chicago Press</publisher><date type="published">2006</date><biblScope unit="vol">194</biblScope><biblScope unit="issue">Supplemet_2</biblScope><biblScope unit="page" from="S73">S73</biblScope><biblScope unit="page" to="S76">S76</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Academies and Institutes (trends)</term><term>Adult</term><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Disease Outbreaks (prevention & control)</term><term>Drug Therapy, Combination</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Global Health</term><term>Health Planning</term><term>Humans</term><term>Infant</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (therapeutic use)</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Oseltamivir (therapeutic use)</term><term>Seasons</term><term>United States (epidemiology)</term><term>Vaccination (trends)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Académies et instituts (tendances)</term><term>Adulte</term><term>Animaux</term><term>Antienzymes (administration et posologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Essais cliniques comme sujet</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Infections à Orthomyxoviridae ()</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Nourrisson</term><term>Oséltamivir (usage thérapeutique)</term><term>Planification en santé</term><term>Saisons</term><term>Santé mondiale</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (usage thérapeutique)</term><term>Vaccination (tendances)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Virus de la grippe A (immunologie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enzyme Inhibitors</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Neuraminidase</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Académies et instituts</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections à Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Academies and Institutes</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Clinical Trials as Topic</term><term>Drug Therapy, Combination</term><term>Global Health</term><term>Health Planning</term><term>Humans</term><term>Infant</term><term>Seasons</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Association de médicaments</term><term>Essais cliniques comme sujet</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Infections à Orthomyxoviridae</term><term>Nourrisson</term><term>Planification en santé</term><term>Saisons</term><term>Santé mondiale</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has been working to enact measures to deal more effectively with a potential influenza pandemic and also to assist in the management of seasonal influenza. The majority of the NIAID’s efforts have been dedicated to basic research aimed ultimately at developing and testing, in clinical trials, countermeasures in the form of antiviral drugs and vaccines. Some of the NIAID’s current and planned antiviral projects include the (1) assessment of oseltamivir therapy in infants, (2) conduct of clinical trials of higher doses of osteltamivir for avian influenza, (3) appraisal of combination therapies, and (4) evaluation of the next generation of neuraminidase inhibitors. In addition, the NIAID is screening potential new antiviral drugs and evaluating novel drug targets. Similarly, significant funding has been committed to vaccine preparedness, and numerous novel candidate influenza vaccines are in various stages of development. Importantly, there is an integral relationship between preparation for seasonal influenza and preparation for pandemic influenza. Until these approaches are firmly linked, the community will not have optimized its preparedness for a pandemic.</div></front></TEI><double doi="10.1086/507550"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures</title><author wicri:is="90%"><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S." last="Fauci">Anthony S. Fauci</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:6FA22D241D5561D559825239E2E3CFCCC62D26F5</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1086/507550</idno><idno type="url">https://api.istex.fr/ark:/67375/HXZ-3K1JXSPC-1/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001691</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001691</idno><idno type="wicri:Area/Istex/Curation">001691</idno><idno type="wicri:Area/Istex/Checkpoint">001707</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001707</idno><idno type="wicri:doubleKey">0022-1899:2006:Fauci A:seasonal:and:pandemic</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures</title><author wicri:is="90%"><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S." last="Fauci">Anthony S. Fauci</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Maryland</region></placeName><wicri:cityArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda</wicri:cityArea></affiliation><affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">The Journal of Infectious Diseases</title><title level="j" type="abbrev">The Journal of Infectious Diseases</title><idno type="ISSN">0022-1899</idno><idno type="eISSN">1537-6613</idno><imprint><publisher>University of Chicago Press</publisher><date type="published">2006</date><biblScope unit="vol">194</biblScope><biblScope unit="issue">Supplemet_2</biblScope><biblScope unit="page" from="S73">S73</biblScope><biblScope unit="page" to="S76">S76</biblScope></imprint><idno type="ISSN">0022-1899</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0022-1899</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has been working to enact measures to deal more effectively with a potential influenza pandemic and also to assist in the management of seasonal influenza. The majority of the NIAID’s efforts have been dedicated to basic research aimed ultimately at developing and testing, in clinical trials, countermeasures in the form of antiviral drugs and vaccines. Some of the NIAID’s current and planned antiviral projects include the (1) assessment of oseltamivir therapy in infants, (2) conduct of clinical trials of higher doses of osteltamivir for avian influenza, (3) appraisal of combination therapies, and (4) evaluation of the next generation of neuraminidase inhibitors. In addition, the NIAID is screening potential new antiviral drugs and evaluating novel drug targets. Similarly, significant funding has been committed to vaccine preparedness, and numerous novel candidate influenza vaccines are in various stages of development. Importantly, there is an integral relationship between preparation for seasonal influenza and preparation for pandemic influenza. Until these approaches are firmly linked, the community will not have optimized its preparedness for a pandemic.</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Seasonal and pandemic influenza preparedness: science and countermeasures.</title><author><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S" last="Fauci">Anthony S. Fauci</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. af10r@nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17163392</idno><idno type="pmid">17163392</idno><idno type="doi">10.1086/507550</idno><idno type="wicri:Area/PubMed/Corpus">001C24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001C24</idno><idno type="wicri:Area/PubMed/Curation">001C24</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001C24</idno><idno type="wicri:Area/PubMed/Checkpoint">001A62</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001A62</idno><idno type="wicri:Area/Ncbi/Merge">000436</idno><idno type="wicri:Area/Ncbi/Curation">000436</idno><idno type="wicri:Area/Ncbi/Checkpoint">000436</idno><idno type="wicri:doubleKey">0022-1899:2006:Fauci A:seasonal:and:pandemic</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Seasonal and pandemic influenza preparedness: science and countermeasures.</title><author><name sortKey="Fauci, Anthony S" sort="Fauci, Anthony S" uniqKey="Fauci A" first="Anthony S" last="Fauci">Anthony S. Fauci</name><affiliation wicri:level="2"><nlm:affiliation>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA. af10r@nih.gov</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="ISSN">0022-1899</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Academies and Institutes (trends)</term><term>Adult</term><term>Animals</term><term>Antiviral Agents (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Disease Outbreaks (prevention & control)</term><term>Drug Therapy, Combination</term><term>Enzyme Inhibitors (administration & dosage)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Global Health</term><term>Health Planning</term><term>Humans</term><term>Infant</term><term>Influenza A virus (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term><term>Neuraminidase (antagonists & inhibitors)</term><term>Neuraminidase (therapeutic use)</term><term>Orthomyxoviridae Infections (drug therapy)</term><term>Orthomyxoviridae Infections (prevention & control)</term><term>Oseltamivir (therapeutic use)</term><term>Seasons</term><term>United States (epidemiology)</term><term>Vaccination (trends)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Académies et instituts (tendances)</term><term>Adulte</term><term>Animaux</term><term>Antienzymes (administration et posologie)</term><term>Antienzymes (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments</term><term>Essais cliniques comme sujet</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Infections à Orthomyxoviridae ()</term><term>Infections à Orthomyxoviridae (traitement médicamenteux)</term><term>Nourrisson</term><term>Oséltamivir (usage thérapeutique)</term><term>Planification en santé</term><term>Saisons</term><term>Santé mondiale</term><term>Sialidase (antagonistes et inhibiteurs)</term><term>Sialidase (usage thérapeutique)</term><term>Vaccination (tendances)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Virus de la grippe A (immunologie)</term><term>États-Unis d'Amérique (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Enzyme Inhibitors</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Neuraminidase</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term><term>Enzyme Inhibitors</term><term>Neuraminidase</term><term>Oseltamivir</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antienzymes</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A virus</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term><term>Orthomyxoviridae Infections</term></keywords><keywords scheme="MESH" qualifier="tendances" xml:lang="fr"><term>Académies et instituts</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term><term>Infections à Orthomyxoviridae</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Academies and Institutes</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antienzymes</term><term>Antiviraux</term><term>Oséltamivir</term><term>Sialidase</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>États-Unis d'Amérique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Animals</term><term>Clinical Trials as Topic</term><term>Drug Therapy, Combination</term><term>Global Health</term><term>Health Planning</term><term>Humans</term><term>Infant</term><term>Seasons</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Animaux</term><term>Association de médicaments</term><term>Essais cliniques comme sujet</term><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Infections à Orthomyxoviridae</term><term>Nourrisson</term><term>Planification en santé</term><term>Saisons</term><term>Santé mondiale</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Influenza has not been treated with the degree of medical attention that the disease warrants. As such, there is not an adequate baseline of preparedness in the United States to deal with the potential of pandemic influenza. The National Institute of Allergy and Infectious Diseases (NIAID) has been working to enact measures to deal more effectively with a potential influenza pandemic and also to assist in the management of seasonal influenza. The majority of the NIAID's efforts have been dedicated to basic research aimed ultimately at developing and testing, in clinical trials, countermeasures in the form of antiviral drugs and vaccines. Some of the NIAID's current and planned antiviral projects include the (1) assessment of oseltamivir therapy in infants, (2) conduct of clinical trials of higher doses of osteltamivir for avian influenza, (3) appraisal of combination therapies, and (4) evaluation of the next generation of neuraminidase inhibitors. In addition, the NIAID is screening potential new antiviral drugs and evaluating novel drug targets. Similarly, significant funding has been committed to vaccine preparedness, and numerous novel candidate influenza vaccines are in various stages of development. Importantly, there is an integral relationship between preparation for seasonal influenza and preparation for pandemic influenza. Until these approaches are firmly linked, the community will not have optimized its preparedness for a pandemic.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005407 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 005407 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= PandemieGrippaleV1
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:6FA22D241D5561D559825239E2E3CFCCC62D26F5
|texte= Seasonal and Pandemic Influenza Preparedness: Science and Countermeasures
}}
| This area was generated with Dilib version V0.6.34. |  |